MedTrace Logo

LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)

NCT03725605 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-12-05

Study results available
· View outcomes & findings →

Summary

ATLAS-IT-04 is a two part, single arm study designed to determine the safety and effectiveness of LTX-315 to induce T-cell infiltration prior to TIL expansion in patients with soft tissue sarcoma. Following intratumoural injection of LTX-315 to a selected lesion, the lesion will be extracted for T-cell culture, expansion and infusion.

Conditions

  • Soft Tissue Sarcoma

Interventions

COMBINATION_PRODUCT

LTX-315 and TILs

Intratumoural injection of LTX-315 and infusion of TILs

Sponsors & Collaborators

  • Herlev Hospital

    collaborator OTHER

  • Lytix Biopharma AS

    lead INDUSTRY

Principal Investigators

  • Inge Marie Svane, MD · Herlev Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-28
Primary Completion
2021-07-02
Completion
2021-10-11

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03725605 on ClinicalTrials.gov